Evaluation of kidney function tests in HIV‐positive patients receiving combined antiretroviral therapy
| Autor: | Mustafa Kemal Çelen, Yasar Yildirim, Emre Aydin, Fatma Yilmaz Aydin, Yakup Demir |
|---|---|
| Přispěvatelé: | Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Aydın, Emre E., Aydın, Fatma Yılmaz, Demir, Yakup, Yıldırım, Yaşar, Çelen, Mustafa Kemal, Aydın, Emre |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Anti-HIV Agents Renal function HIV Infections 030204 cardiovascular system & hematology Kidney Kidney Function Tests Emtricitabine Tenofovir alafenamide Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Abacavir Internal medicine medicine Humans 030212 general & internal medicine Tenofovir business.industry Adenine Cobicistat Lamivudine General Medicine Raltegravir chemistry HIV-positive patients Dolutegravir HIV-1 business medicine.drug |
| Zdroj: | International Journal of Clinical Practice. 75 |
| ISSN: | 1742-1241 1368-5031 |
| DOI: | 10.1111/ijcp.14542 |
| Popis: | Introduction: Human Immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases, and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24-month period in HIV-positive patients who were begun on combined antiretroviral therapy. Material-method: A total of 127 HIV positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as Group 1; those that received Dolutegravir/Abacavir/Lamivudine combination as Group 2; those that received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as Group 3; those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as Group 4; and those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as Group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24-month follow-up period. Results: At the 24th month of therapy, a significant difference was observed between the eGFR levels of the study groups (p:0.05). Serum creatinine level was significantly higher in Groups 4 and 5 compared to the other groups (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|